StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug ...

Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...

On November 21, 2024, Replimune Group, Inc. (NASDAQ: REPL) made significant strides in the advancement of its lead product candidate, RP1. The company announced the submission of a biologics license ...

Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical ...

REGENECYTE™ is an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood. It is approved for unrelated donor hematopoietic progenitor cell transplantation procedures ...

Theratechnologies (TSE:TH) has released an update. Don't Miss our Black Friday Offers: Theratechnologies has resubmitted a supplemental Biologics License Application to the FDA for its F8 formulation ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...